AlphaMadera
Ultragenyx Pharmaceutical Inc. (RARE)
$15.57
-1.59 (-9.27%)Delayed quote.
Price history
Daily close- Start
- $30.95
- Latest close
- $15.57
- Period change
- -49.69%
- Period low
- $12.88
- Period high
- $36.54
Key metrics
- Market cap
- $1.54B
- Volume
- 5.38M
- Average volume
- 3.70M
- 52-week range
- $12.73 – $39.89
- Beta
- 0.32
- Last dividend
- —
- EPS (TTM)
- -$5.19
- P/E ratio
- -3.95
- Revenue (TTM)
- $730.00M
- Net income (TTM)
- -$524.00M
- Total assets
- $1.19B
- Total debt
- $1.19B
- Cash and equivalents
- $150.00M
Key financials (trailing twelve months).
Company profile
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- CEO
- Emil D. Kakkis
- Employees
- 1,371
- Headquarters
- Novato, CA, US
- IPO date
- 2014-01-31
- Website
- https://www.ultragenyx.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $673.00M | $560.23M | $434.25M |
| Gross profit | $564.00M | $483.50M | $389.04M |
| Operating income | -$535.00M | -$535.97M | -$569.21M |
| EBITDA | -$474.00M | -$469.00M | -$516.45M |
| Net income | -$575.00M | -$569.18M | -$606.64M |
| Diluted EPS | -$5.83 | -$6.29 | -$8.25 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $434.00M | $173.73M | $213.58M |
| Total assets | $1.53B | $1.50B | $1.49B |
| Total liabilities | $1.60B | $1.24B | $1.22B |
| Total debt | $1.28B | $40.34M | $43.17M |
| Shareholders’ equity | -$80.00M | $255.30M | $275.41M |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$466.00M | -$414.19M | -$474.81M |
| Capital expenditure | -$6.00M | -$7.49M | -$46.77M |
| Free cash flow | -$472.00M | -$421.68M | -$521.57M |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $173.00M | $214.00M | $136.00M | $207.00M | $159.93M | $166.50M |
| Gross profit | $141.00M | $180.00M | $106.00M | $178.00M | $131.94M | $143.49M |
| Operating income | -$110.00M | -$75.00M | -$169.00M | -$114.00M | -$170.89M | -$107.89M |
| EBITDA | -$101.00M | -$61.00M | -$155.00M | -$100.22M | -$156.79M | -$90.96M |
| Net income | -$118.00M | -$92.00M | -$185.00M | -$129.00M | -$180.41M | -$114.95M |
| Diluted EPS | -$1.16 | -$0.90 | -$1.84 | -$1.29 | -$1.81 | -$1.17 |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $150.00M | $125.00M | $175.00M | $434.00M | $212.34M | $166.11M |
| Total assets | $1.19B | $1.26B | $1.30B | $1.53B | $1.19B | $1.31B |
| Total liabilities | $1.56B | $1.55B | $1.52B | $1.60B | $1.17B | $1.15B |
| Total debt | $1.19B | $1.20B | $1.20B | $1.28B | $884.80M | $36.30M |
| Shareholders’ equity | -$376.00M | -$291.00M | -$236.00M | -$80.00M | $9.16M | $151.29M |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$43.00M | -$97.00M | -$197.00M | -$99.83M | -$91.42M | -$108.27M |
| Capital expenditure | -$2.00M | -$1.00M | -$1.00M | -$938.0K | -$1.28M | $12.54M |
| Free cash flow | -$45.00M | -$98.00M | -$198.00M | -$100.77M | -$92.70M | -$95.73M |